Based on the Niagen Bioscience, Inc. stock forecast from 1 analysts, the average analyst target price for Niagen Bioscience, Inc. is USD 11.00 over the next 12 months. Niagen Bioscience, Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Niagen Bioscience, Inc. is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Niagen Bioscience, Inc.’s stock price was USD 6.76. Niagen Bioscience, Inc.’s stock price has changed by +14.00% over the past week, 0% over the past month and 0% over the last year.
No recent analyst target price found for Niagen Bioscience, Inc.
No recent average analyst rating found for Niagen Bioscience, Inc.
Frequently Asked Questions About Niagen Bioscience, Inc. (NAGE) Stock
Based on ratings from 1 analysts Niagen Bioscience, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on NAGE's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for NAGE is USD 11.00 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 11.
Unfortunately we do not have enough data on NAGE's stock to indicate if its overvalued.
The last closing price of NAGE's stock was USD 6.76.
Unfortunately we do not currently have any market capitalization data for NAGE's stock.
Based on targets from 1 analysts, the average taret price for NAGE is projected at USD 11.00 over the next 12 months.
This means that NAGE's stock price may go up by +62.72% over the next 12 months.
We can't find any ETFs which contains Niagen Bioscience, Inc.'s stock.
Sorry, we do not have any data on the number of employees for Niagen Bioscience, Inc..
Niagen Bioscience, Inc.'s registered address is 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024.
You can get more information about it from Niagen Bioscience, Inc.'s website at https://www.chromadex.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
There is nothing we particularly dislike
Frequently Asked Questions About Niagen Bioscience, Inc. (NAGE) Stock
Based on ratings from 1 analysts Niagen Bioscience, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on NAGE's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for NAGE is USD 11.00 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 11.
Unfortunately we do not have enough data on NAGE's stock to indicate if its overvalued.
The last closing price of NAGE's stock was USD 6.76.
Unfortunately we do not currently have any market capitalization data for NAGE's stock.
Based on targets from 1 analysts, the average taret price for NAGE is projected at USD 11.00 over the next 12 months.
This means that NAGE's stock price may go up by +62.72% over the next 12 months.
We can't find any ETFs which contains Niagen Bioscience, Inc.'s stock.
Sorry, we do not have any data on the number of employees for Niagen Bioscience, Inc..
Niagen Bioscience, Inc.'s registered address is 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024.
You can get more information about it from Niagen Bioscience, Inc.'s website at https://www.chromadex.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NAGE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
